PDCD1 and non-small cell lung carcinoma: While changes in circulating immune cell phenotypes and genetic markers after PD-1 blockade can correlate with clinical response, a limited number of studies have explored the potential of a combined genetic and immune cell phenotype as an early prognostic signature of clinical response in patients with NSCLC [reviewed in (5)].